Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00166439 · ClinicalTrials.gov registry record · Phase 2
Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma
A Phase 2 study, sponsored by Academic and Community Cancer Research United.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00166439 is a Phase 2 study that has completed, run by Academic and Community Cancer Research United. The registered enrollment target is 50 participants.
The verdict
NCT00166439, a Phase 2 study, has completed, sponsored by Academic and Community Cancer Research United.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The goals of this protocol are to determine the effect of oxaliplatin, cytosine arabinoside, and dexamethasone with Rituxan (ROAD) as treatment for patients with relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL).
Interventions
- DRUG Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-03 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00166439
The ClinicalTrials.gov registry entry for NCT00166439 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) is the first listed.
NCT00166439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00166439 about?
NCT00166439 is a clinical study titled "Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma". The goals of this protocol are to determine the effect of oxaliplatin, cytosine arabinoside, and dexamethasone with Rituxan (ROAD) as treatment for patients with relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL).
What is the current status of trial NCT00166439?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2005-03. Estimated completion is 2015-09.
What interventions are being tested in trial NCT00166439?
The interventions under investigation include: Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) (DRUG).
Who is sponsoring clinical trial NCT00166439?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.